Home / AVCRF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does AVCRF make money? Does AVCRF have pricing power? What's the Earnings Whisper? Will AVCRF profit more as the business scales? What is AVCRF's management track record? Is AVCRF's current price justified?

Avricore Health Inc.

$0 -$0.03 (-97.50%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

Day Range

$0$0.04

Year Range

$0$0.08

Market Cap

81.03K

AVG Volume

36.53K

Trailing/Forward PE

-3.41/-

PEG ratio

0.15

Dividend Yield

Next Earnings Date

Primary Exchange

Other OTC

Revenue (CAD) · TTM

AVCRF Revenue (CAD) · TTM by quarter
Period	Revenue (CAD) · TTM
26 Q2	190.7K
26 Q1	144.28K
25 Q4	533.91K
25 Q3	1.92M
25 Q2	3.08M
25 Q1	4.1M
24 Q4	4.79M
24 Q3	4.72M
24 Q2	4.48M
24 Q1	3.98M

Net Income (CAD) · TTM

AVCRF Net Income (CAD) · TTM by quarter
Period	Net Income (CAD) · TTM
26 Q2	-1.79M
26 Q1	-1.99M
25 Q4	-1.86M
25 Q3	-1.63M
25 Q2	-1.43M
25 Q1	-914.88K
24 Q4	-668.98K
24 Q3	103.13K
24 Q2	-2.92K
24 Q1	-341.17K

Operating Income (CAD) · TTM

AVCRF Operating Income (CAD) · TTM by quarter
Period	Operating Income (CAD) · TTM
26 Q2	-1.3M
26 Q1	-1.54M
25 Q4	-1.37M
25 Q3	-842.23K
25 Q2	-636.51K
25 Q1	-93.15K
24 Q4	145.4K
24 Q3	128.47K
24 Q2	19.83K
24 Q1	-334.16K

EBITDA (CAD) · TTM

AVCRF EBITDA (CAD) · TTM by quarter
Period	EBITDA (CAD) · TTM
26 Q2	-1.22M
26 Q1	-1.43M
25 Q4	-1.23M
25 Q3	-593.19K
25 Q2	-319.72K
25 Q1	273.49K
24 Q4	579.2K
24 Q3	572.12K
24 Q2	467.6K
24 Q1	107.11K

Cash Flows (CAD) · TTM

AVCRF Cash Flows (CAD) · TTM by quarter
Period	Cash Flows (CAD) · TTM
26 Q2	-1.11M
26 Q1	-1.06M
25 Q4	-898.25K
25 Q3	-263.49K
25 Q2	230.39K
25 Q1	614.47K
24 Q4	799.27K
24 Q3	351.93K
24 Q2	96.64K
24 Q1	70.68K

EPS (CAD) · TTM

AVCRF EPS (CAD) · TTM by quarter
Period	EPS (CAD) · TTM
26 Q2	-0.02
26 Q1	-0.02
25 Q4	-0.02
25 Q3	-0.02
25 Q2	-0.02
25 Q1	-0.01
24 Q4	-0.01
24 Q3	0
24 Q2	-0
24 Q1	-0

Expenses (CAD) · TTM

AVCRF Expenses (CAD) · TTM by quarter
Period	Expenses (CAD) · TTM
26 Q2	1.18M
26 Q1	1.36M
25 Q4	1.63M
25 Q3	1.89M
25 Q2	2.22M
25 Q1	2.14M
24 Q4	2.06M
24 Q3	2.29M
24 Q2	2.43M
24 Q1	2.78M

Shares Outstanding (CAD) · TTM

AVCRF Shares Outstanding (CAD) · TTM by quarter
Period	Shares Outstanding (CAD) · TTM
26 Q2	-100.32K
26 Q1	-228.67K
25 Q4	-280.68K
25 Q3	-415.73K
25 Q2	-702.32K
25 Q1	-575.56K
24 Q4	-541.16K
24 Q3	-509.92K
24 Q2	-476.15K
24 Q1	-643.08K

Employee Count

AVCRF Employee Count by quarter
Period	Employee Count
2024	1
2023	1
2022	1
2018	2
2017	9
2016	8
2013	350
2012	350
2011	3
2010	3

PE Ratio

AVCRF PE Ratio by quarter
Period	PE Ratio
Jun 25	35.5
Jun 25	56.14
May 25	59.85
May 25	42.87
May 25	47.54
May 25	37.64
May 25	66.88
Apr 25	41.57
Apr 25	41.52
Apr 25	42.82
Apr 25	47.99
Mar 25	64.47
Mar 25	42.21
Mar 25	40.94
Mar 25	22.31
Feb 25	46.62
Feb 25	57.54
Feb 25	57.4
Feb 25	57.82
Jan 25	61.39
Jan 25	60.61
Jan 25	66.15
Jan 25	53.05
Jan 25	57.9

Free Cash Flow Yield

AVCRF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-946.49%
Sep 26	-949.04%
Aug 26	-30.22%
Aug 26	-30.52%
Aug 26	-30.28%
Aug 26	-30.14%
Jul 26	-29.98%
Jul 26	-21.85%
Jul 26	-15.51%
Jul 26	-11.19%
Jul 26	-17.98%
Jun 26	-20.72%
Jun 26	-13.73%
Jun 26	-13.86%
Jun 26	-13.92%
May 26	-20.55%
May 26	-19.78%
May 26	-14.8%
May 26	-4.77%
May 26	-4.42%
Apr 26	-3.16%
Apr 26	-3.17%
Apr 26	-3.18%
Apr 26	-4.04%
Mar 26	-3.18%
Mar 26	-3.39%
Mar 26	-3.57%
Mar 26	-3.13%
Feb 26	-3.49%
Feb 26	-3.19%
Feb 26	-3.61%
Feb 26	-3.66%
Jan 26	-4.27%
Jan 26	-2.73%
Jan 26	-2.87%
Jan 26	-5.94%
Jan 26	-5.91%
Dec 25	6.19%
Dec 25	3.9%
Dec 25	4.75%
Dec 25	5.84%
Nov 25	5.28%
Nov 25	5.23%
Nov 25	4.39%
Nov 25	4.09%
Oct 25	4.09%
Oct 25	4.93%
Oct 25	2.98%
Oct 25	3.35%
Oct 25	4%
Sep 25	3.56%
Sep 25	3.63%
Sep 25	8.92%
Sep 25	8.07%
Aug 25	7.99%
Aug 25	10.4%
Aug 25	9.44%
Aug 25	7.53%
Aug 25	6.46%
Jul 25	6.12%
Jul 25	8.78%
Jul 25	9.29%
Jul 25	13.7%
Jun 25	16.22%
Jun 25	13.51%
Jun 25	9.61%
Jun 25	6.08%
May 25	5.7%
May 25	7.96%
May 25	7.18%
May 25	9.07%
May 25	5.1%
Apr 25	8.21%
Apr 25	8.22%
Apr 25	7.97%
Apr 25	7.11%
Mar 25	5.29%
Mar 25	8.08%
Mar 25	8.34%
Mar 25	15.3%
Feb 25	7.32%
Feb 25	5.93%
Feb 25	5.95%
Feb 25	5.9%
Jan 25	5.56%
Jan 25	5.63%
Jan 25	5.16%
Jan 25	6.43%
Jan 25	5.89%
Dec 24	1.62%
Dec 24	1.63%
Dec 24	1.32%
Dec 24	1.1%
Nov 24	1.79%
Nov 24	1.55%
Nov 24	1.37%
Nov 24	0.61%
Nov 24	0.63%
Oct 24	0.61%
Oct 24	0.53%

Price to Sales

AVCRF Price to Sales by quarter
Period	Price to Sales
Sep 26	0.78
Sep 26	0.78
Aug 26	24.4
Aug 26	24.16
Aug 26	24.35
Aug 26	24.46
Jul 26	24.59
Jul 26	33.74
Jul 26	47.54
Jul 26	15.03
Jul 26	9.35
Jun 26	8.12
Jun 26	12.25
Jun 26	12.14
Jun 26	12.08
May 26	8.19
May 26	8.5
May 26	11.37
May 26	2.88
May 26	3.1
Apr 26	4.34
Apr 26	4.33
Apr 26	4.31
Apr 26	3.4
Mar 26	4.31
Mar 26	4.05
Mar 26	3.84
Mar 26	4.37
Feb 26	3.92
Feb 26	4.3
Feb 26	3.8
Feb 26	3.75
Jan 26	3.21
Jan 26	5.02
Jan 26	4.78
Jan 26	2.31
Jan 26	2.32
Dec 25	1.21
Dec 25	1.92
Dec 25	1.57
Dec 25	1.28
Nov 25	1.42
Nov 25	1.43
Nov 25	1.7
Nov 25	1.83
Oct 25	1.83
Oct 25	1.52
Oct 25	2.51
Oct 25	2.24
Oct 25	1.87
Sep 25	2.1
Sep 25	2.06
Sep 25	1.68
Sep 25	1.86
Aug 25	1.88
Aug 25	1.44
Aug 25	1.59
Aug 25	1.99
Aug 25	2.32
Jul 25	2.45
Jul 25	1.71
Jul 25	1.62
Jul 25	1.1
Jun 25	1.03
Jun 25	1.24
Jun 25	0.78
Jun 25	1.23
May 25	1.31
May 25	0.94
May 25	1.04
May 25	0.82
May 25	1.46
Apr 25	0.91
Apr 25	0.91
Apr 25	0.94
Apr 25	1.05
Mar 25	1.41
Mar 25	0.92
Mar 25	0.89
Mar 25	0.49
Feb 25	1.02
Feb 25	1.26
Feb 25	1.25
Feb 25	1.26
Jan 25	1.34
Jan 25	1.32
Jan 25	1.45
Jan 25	1.16
Jan 25	1.27
Dec 24	1.33
Dec 24	1.33
Dec 24	1.63
Dec 24	1.95
Nov 24	1.21
Nov 24	1.39
Nov 24	1.57
Nov 24	3.56
Nov 24	3.42
Oct 24	3.56
Oct 24	4.06

EV/EBITDA

AVCRF EV/EBITDA by quarter
Period	EV/EBITDA
Sep 25	20.51
Sep 25	23.15
Aug 25	23.43
Aug 25	16.92
Aug 25	19.11
Aug 25	25.17
Aug 25	30.09
Jul 25	32.03
Jul 25	20.9
Jul 25	19.52
Jul 25	11.72
Jun 25	6.54
Jun 25	8.24
Jun 25	5.02
Jun 25	8.74
May 25	9.41
May 25	6.35
May 25	7.19
May 25	5.4
May 25	10.67
Apr 25	6.11
Apr 25	6.1
Apr 25	6.34
Apr 25	7.27
Mar 25	10.24
Mar 25	6.23
Mar 25	6
Mar 25	2.64
Feb 25	7.02
Feb 25	8.99
Feb 25	8.96
Feb 25	9.04
Jan 25	9.68
Jan 25	9.54
Jan 25	10.54
Jan 25	8.18
Jan 25	9.06
Dec 24	11.53
Dec 24	11.5
Dec 24	14.41
Dec 24	17.5
Nov 24	10.36
Nov 24	12.08
Nov 24	13.83
Nov 24	32.87
Nov 24	31.55
Oct 24	32.84
Oct 24	37.69
Oct 24	37.58
Oct 24	46.6
Sep 24	191.86
Sep 24	182.29
Sep 24	182.53
Sep 24	218.74
Aug 24	264.4
Aug 24	269.46
Aug 24	284.86
Aug 24	211.74
Aug 24	285.57
Jul 24	273.25
Jul 24	234.13
Jul 24	159.12
Jul 24	147.51

Price/Operating Cashflow

AVCRF Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Dec 25	9.33
Dec 25	14.78
Dec 25	12.14
Dec 25	9.88
Nov 25	10.93
Nov 25	11.03
Nov 25	13.14
Nov 25	14.11
Oct 25	14.1
Oct 25	11.71
Oct 25	19.34
Oct 25	17.24
Oct 25	14.43
Sep 25	16.23
Sep 25	15.88
Sep 25	8.42
Sep 25	9.3
Aug 25	9.4
Aug 25	7.22
Aug 25	7.95
Aug 25	9.98
Aug 25	11.63
Jul 25	12.27
Jul 25	8.55
Jul 25	8.09
Jul 25	5.48
Jun 25	4.91
Jun 25	5.89
Jun 25	4.04
Jun 25	6.39
May 25	6.81
May 25	4.88
May 25	5.41
May 25	4.28
May 25	7.61
Apr 25	4.73
Apr 25	4.73
Apr 25	4.88
Apr 25	5.46
Mar 25	7.34
Mar 25	4.81
Mar 25	4.66
Mar 25	2.54
Feb 25	5.31
Feb 25	6.55
Feb 25	6.53
Feb 25	6.58
Jan 25	6.99
Jan 25	6.9
Jan 25	7.53
Jan 25	6.04
Jan 25	6.59
Dec 24	7.01
Dec 24	6.99
Dec 24	8.6
Dec 24	10.29
Nov 24	6.37
Nov 24	7.32
Nov 24	8.28
Nov 24	18.75
Nov 24	18.03
Oct 24	18.74
Oct 24	21.41
Oct 24	21.35
Oct 24	26.31
Sep 24	21.72
Sep 24	20.66
Sep 24	20.69
Sep 24	24.67
Aug 24	29.69
Aug 24	30.25
Aug 24	31.94
Aug 24	23.9
Aug 24	32.02
Jul 24	30.67
Jul 24	26.37
Jul 24	18.11
Jul 24	16.84
Jun 24	26.5
Jun 24	26.92
Jun 24	45.7
May 24	39.08
May 24	43.22
Apr 24	24.21
Apr 24	24.4
Apr 24	24.04
Apr 24	34.77
Mar 24	39.05
Feb 24	39.63
Feb 24	34.68
Feb 24	34.61
Feb 24	34.55
Feb 24	39.3
Jan 24	39.25
Jan 24	39.18
Jan 24	34.41
Jan 24	48.77
Dec 23	37.4

Price to Book

AVCRF Price to Book by quarter
Period	Price to Book
Sep 26	0.57
Sep 26	0.57
Aug 26	17.99
Aug 26	17.81
Aug 26	17.95
Aug 26	18.03
Jul 26	18.13
Jul 26	24.87
Jul 26	35.05
Jul 26	20.62
Jul 26	12.83
Jun 26	11.14
Jun 26	16.8
Jun 26	16.65
Jun 26	16.57
May 26	11.23
May 26	11.67
May 26	15.59
May 26	4.27
May 26	4.61
Apr 26	6.44
Apr 26	6.42
Apr 26	6.4
Apr 26	5.04
Mar 26	6.4
Mar 26	6.01
Mar 26	5.7
Mar 26	6.49
Feb 26	5.82
Feb 26	6.37
Feb 26	5.63
Feb 26	5.56
Jan 26	4.76
Jan 26	7.46
Jan 26	7.1
Jan 26	3.43
Jan 26	3.44
Dec 25	2.3
Dec 25	3.64
Dec 25	2.99
Dec 25	2.43
Nov 25	2.69
Nov 25	2.72
Nov 25	3.24
Nov 25	3.48
Oct 25	3.47
Oct 25	2.89
Oct 25	4.76
Oct 25	4.25
Oct 25	3.56
Sep 25	4
Sep 25	3.91
Sep 25	3.53
Sep 25	3.9
Aug 25	3.94
Aug 25	3.03
Aug 25	3.33
Aug 25	4.18
Aug 25	4.87
Jul 25	5.14
Jul 25	3.58
Jul 25	3.39
Jul 25	2.3
Jun 25	2.5
Jun 25	3.01
Jun 25	1.47
Jun 25	2.33
May 25	2.48
May 25	1.78
May 25	1.97
May 25	1.56
May 25	2.77
Apr 25	1.72
Apr 25	1.72
Apr 25	1.77
Apr 25	1.99
Mar 25	2.67
Mar 25	1.75
Mar 25	1.7
Mar 25	0.92
Feb 25	1.93
Feb 25	2.38
Feb 25	2.38
Feb 25	2.4
Jan 25	2.54
Jan 25	2.51
Jan 25	2.74
Jan 25	2.2
Jan 25	2.4
Dec 24	2.62
Dec 24	2.61
Dec 24	3.21
Dec 24	3.84
Nov 24	2.38
Nov 24	2.73
Nov 24	3.09
Nov 24	7
Nov 24	6.73
Oct 24	6.99
Oct 24	7.99

No video analysis for this stock yet. Request one from our team.

News: AVCRF

globenewswire.com · 1 Sep 2026

HealthTab™ Programme Expands Nationally Across England

VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab™ platform.

globenewswire.com · 28 Aug 2026

Avricore Grants Options

VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company's board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 3,300,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.06 per common share.

globenewswire.com · 20 Aug 2026

HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK

VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott's point-of-care testing products through the HealthTab™ platform in the UK.

globenewswire.com · 17 Jun 2026

Avricore Health Closes $1.254 Million Financing

VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces that, further to its news release dated May 20, 2026, the Company has closed its non-brokered private placement for gross proceeds of $1,254,000 by issuing 25,080,000 Units at $0.05 per Unit on June 16, 2026.